155 related articles for article (PubMed ID: 36362594)
1. Serum Leucine-Rich α2 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis.
Horiuchi I; Horiuchi A; Umemura T
J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362594
[TBL] [Abstract][Full Text] [Related]
2. Serum Leucine-Rich α2 Glycoprotein Could Be a Useful Biomarker to Differentiate Patients with Normal Colonic Mucosa from Those with Inflammatory Bowel Disease or Other Forms of Colitis.
Horiuchi I; Horiuchi K; Horiuchi A; Umemura T
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792498
[TBL] [Abstract][Full Text] [Related]
3. Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms.
Hayashi T; Kitamura K; Usami M; Miyazawa M; Nishitani M; Dejima A; Yamamoto M; Kawase S; Funaki M; Orita N; Nakagawa H; Morita K; Iida N; Seki A; Nio K; Kido H; Takayama H; Takeuchi Y; Yamada S; Takatori H; Shimada M; Saito H; Yamamoto D; Toyama T; Yamashita T
Inflamm Intest Dis; 2023 Dec; 8(4):133-142. PubMed ID: 38115911
[TBL] [Abstract][Full Text] [Related]
4. Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis.
Yamazato M; Yanai S; Oizumi T; Eizuka M; Yamada S; Toya Y; Uesugi N; Sugai T; Matsumoto T
World J Clin Cases; 2023 Nov; 11(32):7753-7760. PubMed ID: 38073694
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis.
Matsumoto S; Mashima H
Crohns Colitis 360; 2022 Oct; 4(4):otac039. PubMed ID: 36778513
[TBL] [Abstract][Full Text] [Related]
6. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.
Ichimiya T; Kazama T; Ishigami K; Yokoyama Y; Hayashi Y; Takahashi S; Itoi T; Nakase H
PLoS One; 2023; 18(6):e0286415. PubMed ID: 37352151
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
[TBL] [Abstract][Full Text] [Related]
8. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
[TBL] [Abstract][Full Text] [Related]
9. Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis.
Karashima R; Sagami S; Yamana Y; Maeda M; Hojo A; Miyatani Y; Nakano M; Matsuda T; Hibi T; Kobayashi T
Intest Res; 2024 Jun; ():. PubMed ID: 38835140
[TBL] [Abstract][Full Text] [Related]
10. Serum leucine-rich α2-glycoprotein is elevated in patients with systemic lupus erythematosus and correlates with disease activity.
Ahn SS; Park Y; Jung SM; Song JJ; Park YB; Lee SW
Clin Chim Acta; 2018 Nov; 486():253-258. PubMed ID: 30118672
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.
Yasutomi E; Inokuchi T; Hiraoka S; Takei K; Igawa S; Yamamoto S; Ohmori M; Oka S; Yamasaki Y; Kinugasa H; Takahara M; Harada K; Furukawa M; Itoshima K; Okada K; Otsuka F; Tanaka T; Mitsuhashi T; Kato J; Okada H
Sci Rep; 2021 May; 11(1):11086. PubMed ID: 34045529
[TBL] [Abstract][Full Text] [Related]
12. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
[TBL] [Abstract][Full Text] [Related]
14. Serum leucine-rich alpha-2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy-naïve cases with ulcerative colitis.
Kono M; Komeda Y; Tribonias G; Yoshida S; Nomura K; Handa K; Nagai T; Hagiwara S; Omoto S; Takenaka M; Nishida N; Tsuji N; Kashida H; Kudo M
JGH Open; 2023 Aug; 7(8):579-583. PubMed ID: 37649867
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis.
Tatsumi Y; Kakimoto K; Hara A; Mizuta N; Numa K; Kinoshita N; Nakazawa K; Koshiba R; Hirata Y; Ota K; Miyazaki T; Nakamura S; Sakagami K; Arimitsu S; Ito H; Nishikawa H
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002777
[TBL] [Abstract][Full Text] [Related]
16. Combined serum albumin, fecal immunochemical test, and leucine-rich alpha-2 glycoprotein levels for predicting prognosis in remitting patients with ulcerative colitis.
Nakamura N; Honzawa Y; Nishimon S; Sano Y; Tokutomi Y; Ito Y; Yagi N; Kobayashi S; Aoi M; Tahara T; Fukata N; Fukui T; Naganuma M
Sci Rep; 2023 Aug; 13(1):13863. PubMed ID: 37620642
[TBL] [Abstract][Full Text] [Related]
17. Appendiceal orifice inflammation is associated with proximal extension of disease in patients with ulcerative colitis.
Anzai H; Hata K; Kishikawa J; Ishii H; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Kazama S; Yamaguchi H; Ishihara S; Sunami E; Watanabe T
Colorectal Dis; 2016 Aug; 18(8):O278-82. PubMed ID: 27354363
[TBL] [Abstract][Full Text] [Related]
18. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis.
Sakuraba A; Nemoto N; Hibi N; Ozaki R; Tokunaga S; Kikuchi O; Minowa S; Mitsui T; Miura M; Saito D; Hayashida M; Miyoshi J; Matsuura M; Yoneyama M; Ohnishi H; Hisamatsu T
BMC Gastroenterol; 2021 May; 21(1):197. PubMed ID: 33933033
[TBL] [Abstract][Full Text] [Related]
19. Differentiation of Active Ulcerative Colitis vs Noninflammatory Bowel Disease Proctitis by Transperineal Superb Microvascular Imaging.
Tokushima K; Jimbo K; Suzuki M; Endo Y; Hibio M; Maruyama K; Kashiwagi K; Arai N; Sato M; Kudo T; Hoshino E; Ohtsuka Y; Shimizu T
Inflamm Bowel Dis; 2023 Aug; ():. PubMed ID: 37643765
[TBL] [Abstract][Full Text] [Related]
20. Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn's Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy.
Omori T; Sasaki Y; Koroku M; Murasugi S; Yonezawa M; Nakamura S; Tokushige K
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
